{"id":"mencevax-acwy","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Injection site pain"},{"rate":"10-20","effect":"Injection site erythema"},{"rate":"10-20","effect":"Injection site swelling"},{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsular antigens from Neisseria meningitidis serogroups A, C, W, and Y conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune responses. Upon administration, it triggers both humoral and cellular immunity, leading to the production of bactericidal antibodies that protect against invasive meningococcal disease caused by these four serogroups.","oneSentence":"Mencevax ACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:18.904Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00444951","phase":"PHASE3","title":"Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-02","conditions":"Neisseria Meningitidis, Meningococcal Infections","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neisseria meningitidis serogroups A","C","W and Y vaccine"],"phase":"marketed","status":"active","brandName":"Mencevax® ACWY","genericName":"Mencevax® ACWY","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Mencevax ACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}